Shandong Xinhua Pharmaceutical Company Limited (XIN) - Total Assets
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) holds total assets worth €9.07 Billion EUR (≈ $10.60 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check XIN cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Shandong Xinhua Pharmaceutical Company Limited - Total Assets Trend (2013–2025)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's total assets have evolved over time, based on quarterly financial data. Explore Shandong Xinhua Pharmaceutical Company L (XIN) investment intensity to see how much of total assets are deployed in long-term investments.
Shandong Xinhua Pharmaceutical Company Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Shandong Xinhua Pharmaceutical Company Limited's total assets of €9.07 Billion consist of 43.9% current assets and 56.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.2% |
| Accounts Receivable | €862.39 Million | 9.4% |
| Inventory | €1.32 Billion | 14.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €587.16 Million | 6.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shandong Xinhua Pharmaceutical Company L stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Xinhua Pharmaceutical Company Limited's current assets represent 43.9% of total assets in 2025, an increase from 38.1% in 2013.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2025, up from 10.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, unchanged from 6.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 14.4% of total assets.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Total Assets
Key competitors of Shandong Xinhua Pharmaceutical Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Shandong Xinhua Pharmaceutical Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 1.24 | 1.33 |
| Quick Ratio | 1.23 | 0.87 | 0.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.76 Billion | €764.59 Million | €701.28 Million |
Shandong Xinhua Pharmaceutical Company Limited - Advanced Valuation Insights
This section examines the relationship between Shandong Xinhua Pharmaceutical Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €9.19 Billion |
| Market Capitalization | $135.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Xinhua Pharmaceutical Company Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Xinhua Pharmaceutical Company Limited's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
The table below shows the annual total assets of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €9.19 Billion ≈ $10.74 Billion |
+1.84% |
| 2024-12-31 | €9.02 Billion ≈ $10.54 Billion |
+8.85% |
| 2023-12-31 | €8.29 Billion ≈ $9.69 Billion |
+0.25% |
| 2022-12-31 | €8.27 Billion ≈ $9.66 Billion |
+12.73% |
| 2021-12-31 | €7.33 Billion ≈ $8.57 Billion |
+3.37% |
| 2020-12-31 | €7.09 Billion ≈ $8.29 Billion |
+10.21% |
| 2019-12-31 | €6.44 Billion ≈ $7.52 Billion |
+8.79% |
| 2018-12-31 | €5.92 Billion ≈ $6.92 Billion |
+12.18% |
| 2017-12-31 | €5.27 Billion ≈ $6.17 Billion |
+11.66% |
| 2016-12-31 | €4.72 Billion ≈ $5.52 Billion |
+5.13% |
| 2015-12-31 | €4.49 Billion ≈ $5.25 Billion |
+5.82% |
| 2014-12-31 | €4.25 Billion ≈ $4.96 Billion |
+5.88% |
| 2013-12-31 | €4.01 Billion ≈ $4.69 Billion |
-- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more